Objective
The objectives of this study were to identify key drivers of cost effectiveness in Crohn's disease and to identify key similarities and differences of cost effectiveness between the models.
The results suggest that differences in ICERs between the reconstructed model and the model by Bodger et al. are possibly due to the use of updated efficacy data. The reconstructed model and the model used for the vedolizumab submission to NICE used the same efficacy data and had similar base case results; while the model by Bodger et al. used different and older efficacy analysis and gave very different results. 2, 3 The results of the OWSA suggest that rates of response, remission and AEs are important drivers of cost effectiveness in Crohn's disease. Overall, efficacy data in terms of the rates of response and remission appear to be the most important drivers of the cost effectiveness of treatments for Crohn's disease. The key drivers of cost effectiveness in Crohn's disease
We recreated the economic model described by Bodger et al. using their data. 2 Where information was not available from the publication, or more recent data were available, it was supplemented from documents relating to the NICE appraisal of vedolizumab, in which the manufacturer's economic model was heavily influenced by Bodger et al. 3 Health state costs were taken from Bodger et al. and inflated to 2013/14 values using the Unit Costs of Health and Social Care 2014. 4 Treatment costs were taken from the Monthly Index of Medical Specialities (accessed 16 April 2015) to ensure that these were up-to-date, with the remainder of costs sourced from the vedolizumab submission and updated or inflated as appropriate. 3, 5 Efficacy data, including induction rates of remission and response in addition to maintenance transition probabilities, were taken from the vedolizumab submission as this used a network meta-analysis (NMA). The reconstructed model omitted a relative risk of mortality used in the vedolizumab submission. This gave a higher risk for patients in the surgery health state and the moderate-tosevere health state relative to those who were in less severe states in the vedolizumab submission, and it was criticised by the Evidence Review Group (ERG). 6 The model used a base case 60-year time horizon and utilities from Bodger et al. The deterministic incremental cost-effectiveness ratios (ICERs) for infliximab and adalimumab versus standard care obtained from the reconstructed model were compared with the ICERs reported for the published model. Costs and quality-adjusted life years (QALYs) were taken from the vedolizumab submission to derive ICERs versus standard care. A one-way sensitivity analysis (OWSA) of vedolizumab versus standard care was performed in the reconstructed model using the same assumptions as the submission base case, and the outputs of both models were compared to assess whether the key drivers of the models were consistent.
1. BresMed, Sheffield, UK; 2. Janssen-Cilag Ltd, High Wycombe, UK PGI31 Figure 2 shows the seven most influential parameters for the cost effectiveness of vedolizumab versus standard care in the reconstructed model. The publication by Bodger et al. did not discuss the key drivers of cost effectiveness. 2 The key drivers of the reconstructed model and the vedolizumab submission indicated that these are broadly similar. 3 These include efficacy parameters, rates of response and remission during the induction period, in addition to the percentage of responders who remained in the moderate-to-severe health state at the end of the induction period. Health state utilities and mean age were also key drivers in both models. Adverse event (AE) rates for both arms were important in the vedolizumab submission, and standard care rates was the most influential parameter. 3 These parameters were not as influential for the reconstructed model. Induction rates are likely to be influential as 100% of patients are on active treatment during this phase. If patients on biological treatment do not respond in this phase, they move to standard care (see Figure 1 ) meaning fewer patients remain on treatment in the maintenance phase. If patients move into the remission or mild health states, they have a greater probability of staying there than patients who remain in the moderate-to-severe health state. Furthermore, each health state has an associated cost to reflect resource use. The cost of remission and response are lower than other health states, particularly remission, which is around three times lower than response. This is likely the reason moving to these health states, particularly remission, has such a great impact on cost effectiveness. AE rates may be more influential in the vedolizumab submission as these were treated as a group in the OWSA, rather than individually as in the reconstructed model. Standard care rates may be more influential as these apply to more patients, as patients gradually move to standard care.
Bodger et al. reported base case ICERs versus standard care of £19,050 for infliximab and £7,190 for adalimumab, respectively. 2 In contrast, the reconstructed model reported ICERs of £54,077 and £31,210, respectively. These are similar to the results from the vedolizumab submission model, which gave ICERs of £59,186 and £44,603, respectively, over a 10-year horizon. 3 This suggests that the differences in results are principally due to the use of updated efficacy data from the vedolizumab submission, rather than data from the original publication by Bodger et al. Full results are shown in Table 1 . 
